Poster presentation at ANS 2019 on neurological biomarker detection

This year, GeneWorks will be presenting a poster on detection of 3 important neurological biomarkers at the Australasian Neuroscience Society Annual Conference in Adelaide. 

Poster #121, 2nd Dec (Tuesday), 12-2pm. 

Poster abstract:

Ultrasensitive Detection of Three Neurological Biomarkers In Un-Diseased Dried Blood Spots

Brenton Short 1 , Carmen Tobos 2 , Purvish Patel 2 , David M Rissin 2 , Fanny Elahi 2 3 , Marie Altendahl 3

1. GeneWorks, Thebarton, SA, Australia
2. Quanterix Corporation, Billerica, MA, USA
3. Memory and Aging Centre, University of California San Francisco, San Francisco, CA, USA

Dried blood spots (DBS) have many advantages over traditional sample matrices such as cerebrospinal fluid (CSF), serum, plasma, and whole blood. DBS can be collected via a finger prick and stored at room temperature, eliminating the need for invasive procedures, extensive laboratory equipment, and trained medical professionals However, in a traditional ELISA, low abundance neuronal biomarkers are often only measurable in plasma or CSF, and may not be detectable in DBS. Here, we show the ultra sensitive Simoa ® Neuro 4-Plex Assay can quantitatively measure levels of three biomarkers associated with neuronal damage in normal, un-diseased DBS- glial fibrillary acidic protein (GFAP), neurofilament light protein (NfL) and tau. Samples were evaluated for GFAP, NfL and tau concentration, signal reproducibility, stability at room temperature, and signal specificity. 100% of DBS tested were quantifiable (above LLOQ). Inter-spot measurements were reproducible, with an average 15% coefficient of variation between two blood spots from the same individual. DBS GFAP and tau readings were stable at room temperature for 8 days. GFAP, NfL and tau demonstrated signal specificity from 72-100%. The ability to detect biomarkers of a range of neorological disorders in DBS may facilitate studies of disease in remote communities where the logistics of sample collection and processing have historically made such studies difficult.

To find out more about the applications of the Simoa technology, speak to Brenton Short at the conference, or email brenton.s@geneworks.com.au .

 

BACK